FDA approves Hulio, sixth Humira biosimilar

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.
Hulio (adalimumab-fkjp, Mylan/Fujifilm Kyowa Kirin), a biosimilar to Humira (adalimumab, AbbVie), is a TNF inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.
“We are very pleased with FDA’s approval of Hulio, a biosimilar to the world’s top selling drug

Source link

Related posts

Gluten Sensitivity: Causes and Risk Factors


Surgical Weight Loss May Slow Cellular Aging


Innovation of EUS-guided transmural gallbladder drainage using a novel self-expanding metal stent


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World